StreetAlpha.app
Home › Stocks › DTIL

Precision Biosciences Inc (DTIL)

$7.05
▼ −3.16%
LAST CLOSE · NOV 17

Precision BioSciences develops gene editing treatments for genetic and infectious diseases using its ARCUS platform. It last closed at $7.05 on Nov 17, down 3.16% on the day.

AI Auto Pilots
Is DTIL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$45.0M
+6353.0% vs a year ago
Net income
−$38.5M
−85.6% margin
Free cash flow
−$51.8M
−115.0% margin
Operating margin
−80.3%
−$36.2M operating income
Valuation
Market cap
$196.9M
27.9M shares
P/E
–
Price to sales
4.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$81.7M
At Sep 30
Shareholder equity
$51.8M
Shares outstanding
27.9M
At Oct 29
Fiscal year endsMay
ExchangeNasdaq
Financials history
FY2021: $115.5M$115.5MFY2021FY2022: $25.1M$25.1MFY2022FY2023: $48.7M$48.7MFY2023FY2024: $68.7M$68.7MFY2024FY2025: $34.3M$34.3MFY2025

From DTIL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated DTIL in the past 90 days.
Average 12-month target
No price targets on DTIL in the past 90 days.
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 3Buy$60
OppenheimerInitiated
Jun 9Buy$20
HC Wainwright & Co.Reiterated
May 27Buy$60
DateFirmActionRatingPrice target
Aug 3HC Wainwright & Co.ReiteratedBuy$60
Jun 9OppenheimerInitiatedBuy$20
May 27HC Wainwright & Co.ReiteratedBuy$60
Loading…

Technical Analysis

DTIL · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the 50 day average at $7.01, and the nearest resistance the Pivot at $7.12.

Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$11.2952 week high+60.1%
$7.8020 day average+10.6%
$7.43100 day average+5.4%
$7.37Pivot R1+4.5%
$7.31Swing high (Sep 22)+3.7%
$7.12Pivot+1.0%
$7.05Last close
$7.0150 day average−0.6%
$6.81Pivot S1−3.4%
$6.80200 day average−3.5%
$6.70Swing low (Jul 29)−5.0%
$3.5352 week low−49.9%
Indicators
RSI (14)44.71Middle of its rangeNeutral
MACD0.31Below its signal lineBearish
Stochastic16.0Near the bottom of its rangeOversold
ADX (14)23.2Weak trend
Williams %R-91.2Oversold below −80, overbought above −20Oversold
CCI (20)-44.7Oversold below −100, overbought above 100Neutral
Rate of change+1.1%Change over 10 sessionsBullish
ATR (14)$0.75Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for DTIL

What happened before

See how DTIL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DTIL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DTIL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DTIL in the last 90 days.

Loading…

See today’s whale options flow across the market →

DTIL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 34 selling
  • ▲Held by funds +6.2 pts
  • ▲Funds holding +13
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10996+13.5%
In funds' top 1013−66.7%
Held by funds69.7%63.5%+6.2 pts
New / increased20 / 3331 / 32−15.9%
Reduced / sold out27 / 714 / 13+25.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DTIL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DTIL is in one of them and how their past DTIL trades turned out.

DTIL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DTIL in an article yet. Here's the latest on the wider market.

About Precision Biosciences

Precision BioSciences is a gene editing company based in Durham, North Carolina. It uses its ARCUS platform, a gene editing tool built on a single protein, to develop treatments for genetic and infectious diseases. Its lead programs target chronic hepatitis B and Duchenne muscular dystrophy, and it also partners with iECURE on a treatment for ornithine transcarbamylase deficiency. The company's work is aimed at patients with these serious conditions.

Headquarters
Durham, NC